Hormone may help fight obesity and reduce cholesterol

Research has shown that giving obese rodents a recently identified circulating protein called fibroblast growth factor 21 (FGF21) helps improve their metabolism. Now investigators reporting in the Cell Press journal Cell Metabolism reveal that a variant of FGF21 has similar effects in obese people with type 2 diabetes.

"Our findings suggest that FGF21 has the ability to favorably affect body weight and to partially normalize abnormal lipid levels in patients with diabetes. These are substantial issues and unmet medical needs for patients with obesity and ," says senior author Dr. David Moller, vice president of endocrine and cardiovascular research at Eli Lilly and Company.

Lilly scientists initially identified FGF21 as a novel target for its potential in treating metabolic disorders. Dr. Moller and his colleagues studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in 46 patients with obesity and type 2 diabetes. LY treatment led to decreases in LDL cholesterol and triglycerides, increases in HDL cholesterol, and decreases in atherosclerosis-causing lipoproteins.

LY also reduced body weight and fasting insulin, and it increased adiponectin, a hormone produced by that may augment insulin's effects. While there was only a slight lowering of in patients treated with LY, the study's results indicate that FGF21 is active in humans and suggest that FGF21-based therapies may be effective for treating metabolic disorders.

"We are encouraged by the potential of FGF21 to produce multiple metabolic effects in people with diabetes and are evaluating further concepts for FGF21-based therapies," says Dr. Moller. He notes that most people with diabetes have other risk factors related to metabolic syndrome, including , abdominal obesity, elevated triglycerides, low HDL cholesterol levels, and hypertension. No currently available treatment is able to address more than one of these conditions. "Thus, combination therapy is usually prescribed and often leads to tolerability issues, poor patient compliance, and suboptimal outcomes, all of which provide an incentive to continue the search for new therapeutic approaches," Dr. Moller explains.


Explore further

FGF21 hormone, key to control obesity, also protects against heart diseases in mice

More information: Cell Metabolism, Gaich et al.: "The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes." dx.doi.org/10.1016/j.cmet.2013.08.005
Journal information: Cell Metabolism

Provided by Cell Press
Citation: Hormone may help fight obesity and reduce cholesterol (2013, September 3) retrieved 22 September 2019 from https://medicalxpress.com/news/2013-09-hormone-obesity-cholesterol.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Sep 04, 2013
I much prefer using the new options under my insurance: http://navixmarke...amacare/

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more